Related Experiment Videos
Genetic change in actinic keratoses
Oncogene
|June 20, 1996
Summary
Actinic keratoses (AKs) exhibit frequent genetic changes, including loss of heterozygosity (LOH) and p53 mutations, despite their typically benign clinical course. These genetic alterations in AKs may precede squamous cell carcinoma development.
Area of Science:
- Dermatology
- Oncology
- Cancer Genetics
Background:
- Actinic keratoses (AKs) are common skin lesions with potential to progress to squamous cell carcinoma (SCC).
- AKs are characterized by epidermal dysplasia and a high rate of spontaneous regression.
- Despite a generally benign clinical course, AKs display significant genetic instability.
Purpose of the Study:
- To investigate the frequency and patterns of genetic alterations, specifically loss of heterozygosity (LOH) and p53 mutations, in actinic keratoses.
- To explore the relationship between genetic changes, histological dysplasia, and the expression of p21WAF1/CIP1.
- To compare the genetic landscape of AKs with that of invasive squamous cell carcinoma.
Main Methods:
- Analysis of loss of heterozygosity (LOH) at multiple genetic loci in AK lesions.
- Assessment of p53 mutation status in AKs.
- Evaluation of p21WAF1/CIP1 expression patterns and correlation with genetic alterations and cell proliferation.
Main Results:
- A high frequency of LOH was observed in AKs, with a median loss of four loci and frequent p53 mutations.
- Specific chromosomal regions (3p, 9p, 9q, 13q, 17p, 17q) showed common allele loss, correlating with the degree of dysplasia.
- Disturbed p21WAF1/CIP1 expression was associated with allele loss and increased cell proliferation, potentially representing an early event independent of p53 status.
Conclusions:
- Actinic keratoses harbor substantial genetic instability, including frequent LOH and p53 mutations, exceeding that seen in invasive SCC.
- The observed genetic alterations and p21WAF1/CIP1 expression changes suggest complex early events in AKs.
- The relationship between genetic changes and clinical behavior in non-melanoma skin cancer is not linear.